Cantharidin is under clinical development by Verrica Pharmaceuticals and currently in Phase II for Genital Warts (Condylomata Acuminata). According to GlobalData, Phase II drugs for Genital Warts (Condylomata Acuminata) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cantharidin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cantharidin overview

Cantharidin (Ycanth) acts as a blistering agent or acantholytic. It is formulated as solution for topical application. Ycanth is indicated for the treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

Cantharidin (VP-102) is under development for the treatment of Molluscum contagiousum, common warts (Verruca vulgaris) infections, subungual warts, flat warts, actinic keratosis, genital warts and seborrheic keratosis. The therapeutic candidate consist of  0.7% cantharidin.The drug candidate is a topical film forming solution applied using a VP-102 applicator.

For a complete picture of Cantharidin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.